Be in the know. 20 key reads for Wednesday…

  1. Lilly submits authorization request to FDA for antibody-based COVID-19 therapy (MarketWatch)
  2. Boeing’s Aviation Outlook Is Surprisingly Rosy. What It Means for the Stock. (Barron’s)
  3. The Labor Department’s Latest Blow Against ESG Investing (Barron’s)
  4. Trump Pushes for $1,200 Checks, PPP, and Airline Aid After Ending Stimulus Talks (Barron’s)
  5. House Report Attacks Tech Giants as Monopolists That Stifle Competition (Barron’s)
  6. What Time Is the 2020 Vice Presidential Debate Tonight? Here When It Starts and What to Watch. (Barron’s)
  7. Donald Trump’s COVID-19 treatment is similar to the average American hospitalized with coronavirus. Only faster. (USA Today)
  8. ECB’s Lagarde Pledges No Premature Removal of Monetary Support (Bloomberg)
  9. Wells Fargo Eliminates More Than 700 Jobs in Commercial Banking (Bloomberg)
  10. The US economy can survive without new stimulus until after the election and avoid a double-dip recession, Morgan Stanley’s investment chief says (Business Insider)
  11. Molson Coors (TAP) PT Raised to $62 at Guggenheim, Named ‘Best Idea’ (Street Insider)
  12. Trump says he’d approve 2nd round of stimulus checks after halting relief talks (Fox Business)
  13. SEE IT: Bill Murray joins FBN’s ‘The Claman Countdown’ (Fox Business)
  14. How podcasting became a new front in the streaming wars (Financial Times)
  15. Bill Gates Says Regulatory Approval For Antibody Drugs Could Sharply Reduce COVID-19 Mortality (Benzinga)
  16. Real-World Evidence: The Case of Peru (TrialSiteNews)
  17. Chevron vs. Exxon: Which Is a Better Buy? (U.S. News)
  18. Global Outlook Brightens as U.S. Consumer Imports Reach Pre-Pandemic Levels (Wall Street Journal)
  19. Covid-19 Antibody Drug From Glaxo, Vir Enters Final-Stage Testing (Wall Street Journal)
  20. Hedge funds make pandemic bet on insurance (Reuters)